Evidence map›Paper›PMID 26487055›Full record

ReviewWorld journal of urology2016

Immune checkpoint inhibitors: a new frontier in bladder cancer.

Max Kates, Nikolai A Sopko, Hotaka Matsui, Charles G Drake, Noah M Hahn, Trinity J Bivalacqua

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Immune checkpoint inhibitors for urothelial carcinoma.Investigative and clinical urology · 2018
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Max KatesThe James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, 1800 Orleans Street, Marburg 420, Baltimore, MD, 21287, USA. mkates@jhmi.edu.
Nikolai A SopkoThe James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, 1800 Orleans Street, Marburg 420, Baltimore, MD, 21287, USA.
Hotaka MatsuiThe James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, 1800 Orleans Street, Marburg 420, Baltimore, MD, 21287, USA.
Charles G DrakeThe James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, 1800 Orleans Street, Marburg 420, Baltimore, MD, 21287, USA.
Noah M HahnThe James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, 1800 Orleans Street, Marburg 420, Baltimore, MD, 21287, USA.
Trinity J BivalacquaThe James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, 1800 Orleans Street, Marburg 420, Baltimore, MD, 21287, USA.

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
NCI NIH HHS P30 CA006973
6 · The paper itself

Abstract

Immunotherapy is rapidly changing the field of urologic oncology. In this review, we discuss the role of the immune system in general and place a particular emphasis on the biology of the immune checkpoint and its role in cancer. Bladder cancer, as one of the most immunogenic neoplasms, is an exciting target for immune checkpoint inhibition. Early preclinical data and human trial experience suggest that this new drug class may shape bladder cancer therapy for years to come.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsB7-H1 AntigenCarcinoma, Transitional CellCTLA-4 AntigenHumansImmunotherapyIpilimumabProgrammed Cell Death 1 ReceptorUrinary Bladder NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsatezolizumabB7-H1 AntigenCD274 protein, humanCTLA-4 AntigenIpilimumabpembrolizumabProgrammed Cell Death 1 ReceptorBladder cancerImmune checkpointTumor immunology

Identifiers

PMID26487055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.